Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
Open accessPublished version of a preprint
The DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index.
Abstract
Despite recent advances in the use of immunotherapy, only a minority of patients with small cell lung cancer (SCLC) respond to immune checkpoint blockade (ICB). Here, we show that targeting the DNA damage response (DDR) proteins PARP and checkpoint kinase 1 (CHK1) significantly increased protein and surface expression of PD-L1. PARP or CHK1 inhibition remarkably potentiated the antitumor effect of PD-L1 blockade and augmented cytotoxic T-cell infiltration in multiple immunocompetent SCLC in vivo models. CD8+ T-cell depletion reversed the antitumor effect, demonstrating the role of CD8+ T cells in combined DDR–PD-L1 blockade in SCLC. We further demonstrate that DDR inhibition activated the STING/TBK1/IRF3 innate immune pathway, leading to increased levels of chemokines such as CXCL10 and CCL5 that induced activation and function of cytotoxic T lymphocytes. Knockdown of cGAS and STING successfully reversed the antitumor effect of combined inhibition of DDR and PD-L1. Our results define previously unrecognized innate immune pathway–mediated immunomodulatory functions of DDR proteins and provide a rationale for combining PARP/CHK1 inhibitors and immunotherapies in SCLC. Significance: Our results define previously unrecognized immunomodulatory functions of DDR inhibitors and suggest that adding PARP or CHK1 inhibitors to ICB may enhance treatment efficacy in patients with SCLC. Furthermore, our study supports a role of innate immune STING pathway in DDR-mediated antitumor immunity in SCLC. See related commentary by Hiatt and MacPherson, p. 584. This article is highlighted in the In This Issue feature, p. 565
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Importantly, the administration of PARP inhibitors has been associated with PD-L1 upregulation in various cancer cells regardless of BRCA1/2 status, presumably as a consequence of type I IFN or IFNG signaling (Chabanon et al., 2019; Jiao et al., 2017; Sen et al., 2019; Shen et al., 2019).”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Sen et al., 2019
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Indeed, various ICIs have been successfully harnessed to enhance the therapeutic activity of PARP inhibitors in preclinical tumor models (Ding et al., 2018; Jiao et al., 2017; Sen et al., 2019; Shen et al., 2019; Wang et al., 2019b).”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Sen et al., 2019
The cited source says what the claim attributes to it.
In the citing paper
“Previous studies have suggested that the tumor cell-intrinsic STING pathway may be essential in triggering antitumor immunity in other contexts.47–49”
From Functional tumor cell-intrinsic STING, not host STING, drives local and systemic antitumor immunity and therapy efficacy following cryoablation (2023) · cites this paper as [48]
The cited source says what the claim attributes to it.
In the citing paper
“it has been proposed that tumor cell-intrinsic STING enhances tumor immunogenicity by increasing immune cell activation and triggering tumor cell regression.47–49”
From Functional tumor cell-intrinsic STING, not host STING, drives local and systemic antitumor immunity and therapy efficacy following cryoablation (2023) · cites this paper as [48]
In the citing paper
“Additionally, homologous repair defects, such as pathogenic mutations in BRCA1/2, can lead to enhanced immune response by multiple pathways including the release of cytosolic DNA, promotion of type I IFN signaling, and upregulation of PD-L1 (137-139).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [137]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791 · cited 2×
“For the PARP inhibitor experiments, mice received one of the following treatments: (1) vehicle; (2) olaparib (50 mg/kg daily) 4 times per week; (3) anti–PD-L1 (300 μg) once per week; or (4) combination of olaparib and anti–PD-L1.”
MethodPrimary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway
Sun, L., Wu, J., Du, F., Chen, X., & Chen, Z. J. (2013) · Science · doi:10.1126/science.1232458 · Cited by 4,996
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878 · cited 2×
“For the PARP inhibitor experiments, mice received one of the following treatments: (1) vehicle; (2) olaparib (50 mg/kg daily) 4 times per week; (3) anti–PD-L1 (300 μg) once per week; or (4) combination of olaparib and anti–PD-L1.”
MethodImmune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229 · cited 2×
“For the PARP inhibitor experiments, mice received one of the following treatments: (1) vehicle; (2) olaparib (50 mg/kg daily) 4 times per week; (3) anti–PD-L1 (300 μg) once per week; or (4) combination of olaparib and anti–PD-L1.”
MethodSTING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity
Ishikawa, H., Ma, Z., & Barber, G. N. (2009) · Nature · doi:10.1038/nature08476 · Cited by 2,759
Comprehensive genomic profiles of small cell lung cancer
George, J., Lim, J. S., Jang, S. J., Cun, Y., Ozretić, L., Kong, G., Leenders, F., Lu, X., Fernández-Cuesta, L., Bosco, G., et al. (2015) · Nature · doi:10.1038/nature14664 · Cited by 2,340 · cited 2×
“Also, because the mouse tumors have previously been shown to have low mutation burden (41), future studies to monitor the effects of DDR inhibition in patients with SCLC will be valuable to provide further insights into the effect of DDRmediated STING activation and immune response.”
BackgroundSelf-citationRegulation and function of the cGAS–STING pathway of cytosolic DNA sensing
Chen, Q., Sun, L., & Chen, Z. J. (2016) · Nature Immunology · doi:10.1038/ni.3558 · Cited by 2,333 · cited 14×
“In contrast, treatment with PTX (10 and 20 μmol/L for 48 hours) did not cause any appreciable change in the mRNA expression of IFNβ (Supplementary Fig.”
BackgroundInfluentialSTING is a direct innate immune sensor of cyclic di-GMP
Burdette, D. L., Monroe, K. M., Sotelo-Troha, K., Iwig, J. S., Eckert, B., Hyodo, M., Hayakawa, Y., & Vance, R. E. (2011) · Nature · doi:10.1038/nature10429 · Cited by 1,570
STING: infection, inflammation and cancer.
Barber, G. N. (2015) · Nature Reviews Immunology · doi:10.1038/nri3921 · Cited by 1,313 · cited 14×
“In contrast, treatment with PTX (10 and 20 μmol/L for 48 hours) did not cause any appreciable change in the mRNA expression of IFNβ (Supplementary Fig.”
BackgroundInfluentialThe cGAS–cGAMP–STING pathway connects DNA damage to inflammation, senescence, and cancer
Li, T., & Chen, Z. J. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20180139 · Cited by 1,293
Antonia, S. J., López-Martin, J. A., Bendell, J., Ott, P. A., Taylor, M., Eder, J. P., Jäger, D., Pietanza, M. C., Le, D. T., de Braud, F., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30098-5 · Cited by 1,244
Groom, J. R., & Luster, A. D. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.12.017 · Cited by 988 · cited 1×
“Because CXCL10 and CCL5 are key mediators for the chemotaxis of CD8+ T lymphocytes, and CXCL10 and CCL5 overexpression is associated with the presence of CD8+ T lymphocytes in melanoma and gastric and colorectal cancers (34, 35), we next investigated the previously unexplored link between DDR targeting and chemokine e…”
BackgroundPARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression
Jiao, S., Xia, W., Yamaguchi, H., Wei, Y., Chen, M.-K., Hsu, J.-M., Hsu, J. L., Yu, W.-H., Du, Y., Lee, H.-H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3215 · Cited by 981
Hellmann, M. D., Callahan, M. K., Awad, M. M., Calvo, E., Ascierto, P. A., Atmaca, A., Rizvi, N. A., Hirsch, F. R., Selvaggi, G., Szustakowski, J. D., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.001 · Cited by 893
DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
Sato, H., Niimi, A., Yasuhara, T., Permata, T. B. M., Hagiwara, Y., Isono, M., Nuryadi, E., Sekine, R., Oike, T., Kakoti, S., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01883-9 · Cited by 702 · cited 1×
“Furthermore, some recent reports have demonstrated PD-L1 upregulation by DNA damage (40).”
Byers, L. A., Wang, J., Nilsson, M. B., Fujimoto, J., Saintigny, P., Yordy, J., Giri, U., Peyton, M., Fan, Y. H., Diao, L., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0112 · Cited by 557 · cited 1×
“We have previously shown that PARP is overexpressed in SCLC tumors (14) and that PARP inhibition has activity in preclinical models (15, 25), and recent clinical trials have demonstrated clinical benefit from PARP inhibitors in some patients with SCLC (16, 19).”
BackgroundSelf-citationOtt, P. A., Elez, E., Hiret, S., Kim, D.-W., Morosky, A., Saraf, S., Piperdi, B., & Mehnert, J. M. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.5069 · Cited by 521
The host STING pathway at the interface of cancer and immunity
Corrales, L., McWhirter, S. M., Dubensky, T. W., & Gajewski, T. F. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86892 · Cited by 487
Parkes, E. E., Walker, S. M., Taggart, L. E., McCabe, N., Knight, L. A., Wilkinson, R., McCloskey, K. D., Buckley, N. E., Savage, K. I., Salto-Tellez, M., et al. (2017) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw199 · Cited by 462 · cited 1×
“Previous studies have reported the presence of cytosolic DNA post-S phase damage, and additional evidence suggests that cells may actively export DNA fragments from the nucleus, possibly to prevent misincorporation into genomic DNA (42).”
BackgroundPietanza, M. C., Waqar, S. N., Krug, L. M., Dowlati, A., Hann, C. L., Chiappori, A., Owonikoko, T. K., Woo, K. M., Cardnell, R. J., Fujimoto, J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.7672 · Cited by 399 · cited 1×
“We have previously shown that PARP is overexpressed in SCLC tumors (14) and that PARP inhibition has activity in preclinical models (15, 25), and recent clinical trials have demonstrated clinical benefit from PARP inhibitors in some patients with SCLC (16, 19).”
BackgroundSelf-citationde Bono, J., Ramanathan, R. K., Mina, L., Chugh, R., Glaspy, J., Rafii, S., Kaye, S., Sachdev, J., Heymach, J., Smith, D. C., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1250 · Cited by 387 · cited 1×
“We have previously shown that PARP is overexpressed in SCLC tumors (14) and that PARP inhibition has activity in preclinical models (15, 25), and recent clinical trials have demonstrated clinical benefit from PARP inhibitors in some patients with SCLC (16, 19).”
BackgroundSelf-citationJahchan, N. S., Dudley, J. T., Mazur, P. K., Flores, N., Yang, D., Palmerton, A., Zmoos, A.-F., Vaka, D., Tran, K. Q. T., Zhou, M., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0183 · Cited by 358
Self-citationLoss of p130 Accelerates Tumor Development in a Mouse Model for Human Small-Cell Lung Carcinoma
Schaffer, B. E., Park, K.-S., Yiu, G., Conklin, J. F., Lin, C., Burkhart, D. L., Karnezis, A. N., Sweet-Cordero, E. A., & Sage, J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4228 · Cited by 253 · cited 1×
“The RPP conditional knockout mouse model induced by intratracheal administration of Ad-CMV-Cre for SCLC has been described previously (24).”
MethodSelf-citationThe DNA Damage Response Induces IFN
Brzostek-Racine, S., Gordon, C., Van Scoy, S., & Reich, N. C. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100040 · Cited by 234 · cited 1×
“To test whether the STING pathway was activated in SCLC models in response to the DDR inhibitors prexasertib and olaparib (31), we treated SCLC cell lines and tumors with prexasertib and olaparib and assessed STING pathway activation by transcriptomic and proteomic assays.”
MethodSen, T., Tong, P., Stewart, C. A., Cristea, S., Valliani, A., Shames, D. S., Redwood, A. B., Fan, Y. H., Li, L., Glisson, B. S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3409 · Cited by 194 · cited 2×
“, total 48 mg/kg/week), previously shown to cause growth delay but not tumor regression (18), on flank tumors grown in immunocompromised (nude) versus IC (B6129F1) mice.”
BackgroundMethodSelf-citationCardnell, R. J., Feng, Y., Diao, L., Fan, Y.-H., Masrorpour, F., Wang, J., Shen, Y., Mills, G. B., Minna, J. D., Heymach, J. V., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1975 · Cited by 178 · cited 1×
“We have previously shown that PARP is overexpressed in SCLC tumors (14) and that PARP inhibition has activity in preclinical models (15, 25), and recent clinical trials have demonstrated clinical benefit from PARP inhibitors in some patients with SCLC (16, 19).”
BackgroundSelf-citationIshii, H., Azuma, K., Kawahara, A., Yamada, K., Imamura, Y., Tokito, T., Kinoshita, T., Kage, M., & Hoshino, T. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000414 · Cited by 177
Cardnell, R. J. G., & Byers, L. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3391 · Cited by 165
Self-citationDNA damage and innate immunity: links and trade-offs
Chatzinikolaou, G., Karakasilioti, I., & Garinis, G. A. (2014) · Trends in Immunology · doi:10.1016/j.it.2014.06.003 · Cited by 158
Sen, T., Tong, P., Diao, L., Li, L., Fan, Y.-H., Hoff, J. A., Heymach, J. V., Wang, J., & Byers, L. A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1284 · Cited by 143
Self-citationTargeting DNA damage repair in small cell lung cancer and the biomarker landscape
Sen, T., Gay, C. M., & Byers, L. A. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.02.03 · Cited by 142 · cited 1×
“SCLC exhibits ubiquitous loss in two key regulators of the DNA damage and cell-cycle checkpoint pathway, TP53 and RB1, which leads to high genomic instability and replication stress (20, 41).”
BackgroundSelf-citationAndrogen receptor gene mutations in hormone-refractory prostate cancer
Wall�n, M., Linja, M. J., Kaartinen, K., Schleutker, J., & Visakorpi, T. (1999) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199912)189:4<552::aid-path469>3.0.co;2-i · Cited by 115 · cited 1×
“Because CXCL10 and CCL5 are key mediators for the chemotaxis of CD8+ T lymphocytes, and CXCL10 and CCL5 overexpression is associated with the presence of CD8+ T lymphocytes in melanoma and gastric and colorectal cancers (34, 35), we next investigated the previously unexplored link between DDR targeting and chemokine e…”
BackgroundWang, W., Hodkinson, P. S., McLaren, F., MacKinnon, A. C., Wallace, W. A., Howie, S., & Sethi, T. (2012) · International Journal of Cancer · doi:10.1002/ijc.27613 · Cited by 109 · cited 1×
“Despite having one of the highest mutational burdens among solid tumors, SCLC paradoxically shows lower expression of PD-L1 and relatively immunosuppressed phenotypes with low levels of infiltrating T cells and reduced antigen presentation (38).”
BackgroundActivation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer
Cardnell, R. J., Feng, Y., Mukherjee, S., Diao, L., Tong, P., Stewart, C. A., Masrorpour, F., Fan, Y.-H., Nilsson, M. B., Shen, Y., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152584 · Cited by 93 · cited 1×
“We have previously shown that PARP is overexpressed in SCLC tumors (14) and that PARP inhibition has activity in preclinical models (15, 25), and recent clinical trials have demonstrated clinical benefit from PARP inhibitors in some patients with SCLC (16, 19).”
BackgroundSelf-citationLiu, Y., Li, Y., Liu, S., Adeegbe, D. O., Christensen, C. L., Quinn, M. M., Dries, R., Han, S., Buczkowski, K. A., Wang, X., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0161 · Cited by 52 · cited 1×
“Further studies will be necessary to carefully interrogate the contribution, if any, of the neoantigen load and other immune cell populations, such as natural killer cells (43), during DDR-mediated T-cell activation.”
BackgroundYamane, H., Isozaki, H., Takeyama, M., Ochi, N., Kudo, K., Honda, Y., Yamagishi, T., Kubo, T., Kiura, K., & Takigawa, N. (2015) · Europe PMC (PubMed Central) · Cited by 30
Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel?
Paglialunga, L., Salih, Z., Ricciuti, B., & Califano, R. (2016) · ESMO Open · doi:10.1136/esmoopen-2015-000022 · Cited by 20
Vranić, S. (2017) · Bosnian Journal of Basic Medical Sciences · doi:10.17305/bjbms.2017.2366 · Cited by 18
Cheng, Y., Li, H., Liu, Y., Ma, L., Liu, X., Liu, Y., Liu, J., & Zhang, S. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.7574 · Cited by 8
Small-cell lung cancer in the era of immunotherapy
Majem, M., & Rudin, C. M. (2017) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.10.06 · Cited by 8
Li, H., Liu, Y., Liu, Y., Liu, J., Zhao, D., Wang, Y., & Cheng, Y. (2017) · PubMed Central · doi:10.3779/j.issn.1009-3419.2017.11.06 · Cited by 5
Cited by
Rudin, C. M., Brambilla, E., Faivre-Finn, C., & Sage, J. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00235-0 · Cited by 1,570
Self-citationMolecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
Rudin, C. M., Poirier, J. T., Byers, L. A., Dive, C., Dowlati, A., George, J., Heymach, J. V., Johnson, J. E., Lehman, J. M., MacPherson, D., et al. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0133-9 · Cited by 1,254
Self-citationThe Cytosolic DNA-Sensing cGAS–STING Pathway in Cancer
Kwon, J., & Bakhoum, S. F. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0761 · Cited by 1,293
Gay, C. M., Stewart, C. A., Park, E. M., Diao, L., Groves, S. M., Heeke, S., Nabet, B. Y., Fujimoto, J., Solis, L. M., Lu, W., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.014 · Cited by 962
Self-citationInflammatory microenvironment remodelling by tumour cells after radiotherapy
McLaughlin, M., Patin, E. C., Pedersen, M., Wilkins, A., Dillon, M. T., Melcher, A. A., & Harrington, K. J. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0246-1 · Cited by 883
Metadata
- Authors
- Sen, T., Rodriguez, B. L., Chen, L., Corte, C. M. D., Morikawa, N., Fujimoto, J., Cristea, S., Nguyen, T., Diao, L., Li, L., Fan, Y., Yang, Y., Wang, J., Glisson, B. S., Wistuba, I. I., Sage, J., Heymach, J. V., Gibbons, D. L., & Byers, L. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Stanford Medicine (US)
- 1Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- Corresponding author
- Byers, Lauren A.
- ORCID
- Venue
- Cancer Discovery
- Published
- 2019-05-01
- Volume
- 9
- Issue
- 5
- Pages
- 646-661
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC6563834
- OpenAlex
- W2915645504
- Cited by
- 902
- References
- 47
- Citations by year
- 2026: 84 · 2025: 121 · 2024: 116 · 2023: 130 · 2022: 151 · 2021: 154 · 2020: 103 · 2019: 42
- FWCI
- 47.55
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Funders
- HHS | NIH | National Cancer InstituteHHS | NIH | National Cancer Institute (NCI) (U01-CA213273, R01-CA207295, P30-CA016672, P50-CA070907)
- Lung Cancer Research FoundationLung Cancer Research Foundation (LCRF)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Keywords
- small cell lung cancer, DNA damage response, PARP inhibitors, CHK1 inhibitor, PD-L1 blockade, immune checkpoint blockade, STING pathway, T cell activation, CD8+ T cells, innate immunity, cGAS, CXCL10, RANTES, antitumor immunity, combination immunotherapy
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, STING Protein, Animals, DNA Damage, Female, Humans, Lung Neoplasms, Lymphocyte Activation, Membrane Proteins, Mice, Nude, Phthalazines, Piperazines, Pyrazines, Pyrazoles, Random Allocation, T-Lymphocytes, Cytotoxic, Tumor Cells, Cultured, Apoptosis, Protein Serine-Threonine Kinases, CD8-Positive T-Lymphocytes, Xenograft Model Antitumor Assays, Protein Kinase Inhibitors, Cell Proliferation, Interferon Regulatory Factor-3, Mice, Small Cell Lung Carcinoma, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.